Skip to main content

Table 1 Patient characteristics at time of first orlistat prescription during the follow up period (1st Jan 2006 -30th Nov 2009)

From: Unplanned medication discontinuation as a potential pharmacovigilance signal: a nested young person cohort study

  Orlistat population Male Female
(N = 79) (N = 15) (N = 64)
  (19% of total) (81% of total)
Age n (%)
Children (under 17 years) 24 (30.5%) 4 (26.7%) 20 (31.3%)
Young people (17 – 18 years) 55 (69.6%) 11 (73.3%) 44 (68.7%)
Median (IQR) 17 (16–18)
BMI SDS n (%)
<2.5 12 (15.2%) 0 12 (18.8%)
2.5 – 3.49 24 (30.4%) 6 (40%) 18 (28.1%)
>3.5 18 (22.8%) 6 (40%) 12 (18.8%)
Missing 25 (31.6%) 3 (20%) 22 (34.4%)
Mean (SD) 3.13 (1.0)
Deprivation SIMD (2006) n (%)
1-2 (least deprived) 8 (10.1%) 1 (6.7%) 7 (10.9%)
3-4 7 (8.9%) 2 (13.3%) 5 (7.8%)
5-6 20 (25.3%) 3 (20.0%) 17 (26.6%)
7-8 18 (22.8%) 7 (46.7%) 11 (17.2%)
9-10 (most deprived) 26 (32.9%)* 2 (13.3%) 24 (37.5%)
Co-prescribed drug classes n (%)
0 24 (30.4%) 7 (46.7%) 17 (26.6%)
1-4 52 (65.8%) 8 (53.3%) 44 (68.8%)
>4 3 (3.8%) 0 (0.0%) 3 (4.7%)
Median (IQR) 1 (0–2)
  1. All percentage calculated from column total. *Chi squared test for trend p = 0.03.
  2. SIMD: Scottish Index of Multiple Deprivation, IQR: Inter-quartile range, BMI SDS: Body mass index standard deviation score.